Arcturus Therapeutics partners with Thermo Fisher to develop ARCT-032, an mRNA therapy for cystic fibrosis, boosting its stock price.
Arcturus Therapeutics (ARCT) saw its shares rise after announcing a collaboration with Thermo Fisher Scientific (TMO) to advance ARCT-032, an experimental mRNA therapy for cystic fibrosis. The partnership aims to accelerate development of the treatment for the genetic disorder.
The deal marks a strategic move for Arcturus, which specializes in messenger RNA medicines. Cystic fibrosis affects approximately 70,000 people worldwide, with limited treatment options currently available. Thermo Fisher’s involvement may enhance manufacturing and distribution capabilities.
Shares of ARCT climbed following the announcement, reflecting investor optimism about the therapy’s potential and the partnership’s impact on the company’s pipeline.